You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Issues with anti-Gr1 antibody-mediated myeloid-derived suppressor cell depletion’ by Xing et al
Free
  1. Xiang-Yang Wang1,2,3,
  2. Huanfa Yi4,
  3. Juan Li5,6
  1. 1Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
  2. 2Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
  3. 3Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
  4. 4Institute of Immunology, The First Bethune Hospital Academy of Translational Medicine, Jilin University, Changchun, Jilin, China
  5. 5Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
  6. 6Department of Traditional Chinese Internal Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China
  1. Correspondence to Professor Xiang-Yang Wang, Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA; xiang-yang.wang{at}vcuhealth.org

https://doi.org/10.1136/annrheumdis-2016-209848

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Myeloid-derived suppressor cell (MDSC) is a heterogeneous myeloid cell population that can broadly be characterised as CD11b+Gr-1+ cells in mice. MDSC can be further classified into two main cell subsets, granulocytic MDSC (G-MDSC, CD11b+Ly6ClowLy6G+) and monocytic MDSC (M-MDSC, CD11b+Ly6ChighLy6G−).1 To address the role of MDSC in disease settings (eg, cancer and autoimmune disorders) and to evaluate the potential therapeutic benefits of targeting MDSC in preclinical models, different strategies, including anti-Gr-1 antibodies2–5 and pharmacological inhibitors (eg, gemcitabine and 5-fluorouracil),6 ,7 have been widely used to selectively remove mouse MDSC. The use of these reagents in combination with appropriate experimental systems has advanced significantly our current understanding of these myeloid cells in multiple physiological and pathological processes. Xing et al8 raised an issue with the use of anti-Gr-1 (RB6-8C5) for depletion of MDSC, which indeed has long been recognised by the research community. Anti-Gr-1 antibodies can bind to two Ly6 superfamily molecules, Ly6G and Ly6C, which are preferentially expressed on the granulocytes and monocytes, respectively. The differential expression levels of Gr-1 on G-MDSC and M-MDSC may result in different sensitivities to cross-linking of or depletion …

    View Full Text

    Linked Articles